Literature DB >> 34915476

Clinical Usefulness of Endometrial Cytology in Determining the Therapeutic Effect of Fertility Preserving Therapy.

Takuma Yoshimura1, Wataru Yamagami2, Mio Takahashi2, Takuro Hirano3, Kensuke Sakai2, Takeshi Makabe2, Tatsuyuki Chiyoda2, Kouji Banno2, Daisuke Aoki2.   

Abstract

INTRODUCTION: The significance of endometrial cytology in determining the therapeutic efficacy of medroxyprogesterone acetate (MPA) therapy is unclear. This study aimed to evaluate the clinical usefulness of endometrial cytology during MPA therapy.
METHODS: Overall, 77 patients who underwent dilatation and curettage (D&C) to evaluate the therapeutic efficacy of MPA therapy at our hospital between January 2018 and December 2019 were retrospectively analyzed. The results of D&C, cytological evaluation, and other clinicopathological factors were analyzed based on the patients' medical records.
RESULTS: The sensitivity and specificity of cytology were 61% and 92%, respectively, with D&C being the gold standard for diagnosis in 142 D&C/cytological examinations. Among patients with no residual disease on D&C, 5 (4%) had suspicious or positive cytology. Although MPA therapy was terminated in 3 of these patients, only 1 patient had early recurrence, and the frequency of recurrence was similar to that of patients who showed negative results in both D&C and cytology. DISCUSSION/
CONCLUSION: The sensitivity of endometrial cytology in determining the therapeutic effect of MPA therapy is low, and we confirmed that the omission of D&C is unacceptable. Our findings also suggested that the addition of cytological evaluation to D&C during MPA therapy had a low clinical significance.
© 2021 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Endometrial cancer; Endometrial cytology; Gynecologic oncology; Medroxyprogesterone acetate therapy; Sensitivity; Specificity

Mesh:

Substances:

Year:  2021        PMID: 34915476      PMCID: PMC8985004          DOI: 10.1159/000520701

Source DB:  PubMed          Journal:  Acta Cytol        ISSN: 0001-5547            Impact factor:   2.319


  6 in total

1.  Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Wui-Jin Koh; Nadeem R Abu-Rustum; Sarah Bean; Kristin Bradley; Susana M Campos; Kathleen R Cho; Hye Sook Chon; Christina Chu; David Cohn; Marta Ann Crispens; Shari Damast; Oliver Dorigo; Patricia J Eifel; Christine M Fisher; Peter Frederick; David K Gaffney; Suzanne George; Ernest Han; Susan Higgins; Warner K Huh; John R Lurain; Andrea Mariani; David Mutch; Christa Nagel; Larissa Nekhlyudov; Amanda Nickles Fader; Steven W Remmenga; R Kevin Reynolds; Todd Tillmanns; Stefanie Ueda; Emily Wyse; Catheryn M Yashar; Nicole R McMillian; Jillian L Scavone
Journal:  J Natl Compr Canc Netw       Date:  2018-02       Impact factor: 11.908

2.  Antecedents of Abnormally Invasive Placenta in Primiparous Women: Risk Associated With Gynecologic Procedures.

Authors:  Heather J Baldwin; Jillian A Patterson; Tanya A Nippita; Siranda Torvaldsen; Ibinabo Ibiebele; Judy M Simpson; Jane B Ford
Journal:  Obstet Gynecol       Date:  2018-02       Impact factor: 7.661

3.  ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma.

Authors:  Nicole Concin; Carien L Creutzberg; Ignace Vergote; David Cibula; Mansoor Raza Mirza; Simone Marnitz; Jonathan A Ledermann; Tjalling Bosse; Cyrus Chargari; Anna Fagotti; Christina Fotopoulou; Antonio González-Martín; Sigurd F Lax; Domenica Lorusso; Christian Marth; Philippe Morice; Remi A Nout; Dearbhaile E O'Donnell; Denis Querleu; Maria Rosaria Raspollini; Jalid Sehouli; Alina E Sturdza; Alexandra Taylor; Anneke M Westermann; Pauline Wimberger; Nicoletta Colombo; François Planchamp; Xavier Matias-Guiu
Journal:  Virchows Arch       Date:  2021-02       Impact factor: 4.064

4.  Evaluation of endometrial cytology: cytohistological correlations in 1,441 cancer patients.

Authors:  Hiroyuki Fujiwara; Yoshifumi Takahashi; Masashi Takano; Morikazu Miyamoto; Kazuto Nakamura; Yoshibumi Kaneta; Tatsuya Hanaoka; Michitaka Ohwada; Takanori Sakamoto; Takashi Hirakawa; Keiichi Fujiwara; Mitsuaki Suzuki
Journal:  Oncology       Date:  2014-10-14       Impact factor: 2.935

5.  Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility?

Authors:  Wataru Yamagami; Nobuyuki Susumu; Takeshi Makabe; Kensuke Sakai; Hiroyuki Nomura; Fumio Kataoka; Akira Hirasawa; Kouji Banno; Daisuke Aoki
Journal:  J Gynecol Oncol       Date:  2018-01-02       Impact factor: 4.401

6.  Japan Society of Gynecologic Oncology 2018 guidelines for treatment of uterine body neoplasms.

Authors:  Wataru Yamagami; Mikio Mikami; Satoru Nagase; Tsutomu Tabata; Yoichi Kobayashi; Masanori Kaneuchi; Hiroaki Kobayashi; Hidekazu Yamada; Kiyoshi Hasegawa; Hiroyuki Fujiwara; Hidetaka Katabuchi; Daisuke Aoki
Journal:  J Gynecol Oncol       Date:  2019-10-17       Impact factor: 4.401

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.